Amano K, Harada Y, Shoda T, Nishijima M, Hiraishi S
Department of Obstetrics and Gynecology, Kitasato University School of Medicine, Kanagawa, Japan.
Fetal Diagn Ther. 1997 Nov-Dec;12(6):328-31. doi: 10.1159/000264498.
Efficacy of flecainide acetate for the treatment of fetal supraventricular tachycardia with cardiac failure was reported.
For a case in which maternal digoxin therapy failed, flecainide acetate (400 mg/day) is used from 27 weeks. Cardioversion with improved cardiac function occurred 6 days after treatment. Fetal serum flecainide acetate level was 292 ng/ml which was 64% of the maternal level (453 ng/ml). No adverse maternal side effects were noted with 11 weeks of therapy. A vigorous male baby, weighing 3,610 g, Apgar 8/9, Ua-pH 7.24, was born. He is now 1 year of age and in good condition with medication of 5 mg/kg flecainide acetate.
Flecainide acetate seemed to be safe for both mother and fetus, and effective for the treatment of fetal supraventricular tachycardia which is refractory to transplacental digoxin therapy.
有报道称醋酸氟卡尼治疗胎儿室上性心动过速合并心力衰竭有效。
对于1例母亲使用地高辛治疗失败的病例，从孕27周起使用醋酸氟卡尼（400毫克/天）。治疗6天后发生心脏复律且心功能改善。胎儿血清醋酸氟卡尼水平为292纳克/毫升，为母亲水平（453纳克/毫升）的64%。治疗11周未发现母亲有不良副作用。一名体重3610克、阿氏评分8/9、脐动脉血pH值7.24的健康男婴出生。他现在1岁，状况良好，服用5毫克/千克醋酸氟卡尼。
醋酸氟卡尼对母亲和胎儿似乎都是安全的，对经胎盘使用地高辛治疗无效的胎儿室上性心动过速有效。
